JERUSALEM and NEEDHAM, Massachusetts, October 15 /PRNewswire/ --         Oridion Systems Ltd. - (SWX: ORIDN) is launching at this week's 
American Society of Anesthesiologists Annual Meeting in San Francisco, CA 
its total solution Microstream(R) Monitoring System (MSM(TM)), powered by 
the Bernoulli(R) Enterprise system. The MSM system, a wireless technology for 
continuous central station monitoring, is the only fully integrated 
ventilation and oxygenation remote patient monitoring system that directly 
responded to the Anesthesia Patient Safety Foundation (APSF) recommendation 
for improved Anesthesia Patient Safety Foundation (APSF) recommendation for 
improved ventilation and oxygenation monitoring for patients receiving 
patient controlled analgesia.

Included in the 2006 APSF recommendations was the endorsement of
remote access to alarms, especially on the general floor environment where
higher patient-to-nurse ratios often do not allow on-going visual contact
with the patient as in other areas, such as the intensive care units and
emergency room. The MSM system helps improve patient safety because it
instantaneously alerts clinicians via wireless technology that a patient is
in respiratory distress.

With the MSM system, clinicians have the benefit of closely
monitoring not just oxygenation status (oxygen carried in the blood), but
also the essential ventilation parameter - end-tidal carbon dioxide. Clinical
studies have demonstrated conclusively that carbon dioxide monitoring is the
earliest indication of a change in a patient's ventilation.

The MSM powered by Bernoulli is the only central monitoring
system that supports the full range of Oridion capnography monitoring
products, including the Capnostream(TM) 20 and the patented Microstream
FilterLine(R) sets for CO2 sampling.

Gerry Feldman, President of Oridion Capnography, Inc. said, "With
this system we have been able to deliver information about respiration and
ventilation that has never been experienced before. Its clinical impact is
seen on the faces of our customers who are able to report they can intervene
earlier and more accurately in crisis situations. This system, including the
new recently FDA approved SARA software (Smart Alarm Respiratory Analysis)
that safely reduces alarms by 55%, is the first responder to the
recommendations of the APSF."

Oridion is the global leader of innovative capnography monitoring
solutions in the critical care, pain management, procedural sedation and
emergency medicine settings. The Oridion innovative Microstream technology
continues to be the industry gold standard for monitoring patient ventilation
in this broad range of clinical settings.

The CPC Bernoulli Enterprise System offers state of the art
software and telemedicine solutions, which provide continuous, central, and
remote, real-time surveillance of the patient bedside from a plurality of
medical devices. Along with documenting, storing, and trending patient data,
the system offers instantaneous remote alarm notifications via centralized
monitoring and hand-held or paging systems.

About Oridion

Oridion Systems Ltd. (www.oridion.com) is a global medical device
company specializing in patient safety monitoring. The Company operates
through wholly owned subsidiaries in the United States, Europe, and Israel.

Oridion develops proprietary medical devices and patient
interfaces, based on its patented Microstream(R) technologies, for the
enhancement of patient safety through the monitoring of the carbon dioxide
(CO2) in a patient's breath. These products provide effective, proven airway
management and are used in various clinical environments, including
procedural sedation, pain management, operating rooms, critical care units,
post-anesthesia care units, emergency medical services, transport, alternate
care and other settings where patients' ventilation may be compromised and at
risk.

About Cardiopulmonary Corporation

Cardiopulmonary Corp. (CPC) located in Milford, CT, offers the
Bernoulli(R) Enterprise System software and telemedicine solutions, which
provide continuous, central, and remote, real-time surveillance of the
patient bedside from a plurality of medical devices. Bernoulli(R) uses
web-based and state of the art wired or wireless network technology to
interface with medical devices that have RS-232, Ethernet, or nurse call data
interfaces. Bernoulli(R) documents and stores routine status checks, which
are mandated on patient monitors, ventilators, and other medical devices, by
the Joint Commission of Healthcare Organizations (JCAHO), thus reducing the
time clinicians typically spend on documentation and improving the accuracy
of the reporting through the elimination of transcribing errors.
Instantaneous central station monitoring, and hand-held devices or pager
notifications, of patient alarms, settings, and patient values allow quick
management of alarm conditions. The system also trends patient data,
increasing the accuracy of patient assessment.

Certain statements made herein that are not historical are
forward-looking within the meaning of the Private Securities Litigation
Reform Act of 1995. The words "estimate" "project" "intend" "expect"
"believe" and similar expressions are intended to identify forward-looking
statements. These forward-looking statements involve known and unknown risks
and uncertainties. Many factors could cause the actual results, performance
or achievements of the Company to be materially different from any future
results, performance or achievements that may be expressed or implied by such
forward-looking statements, including, among others, our ability to maintain
profits, the market demands for our Capnography products, our ability to
focus our team on the Capnography business, changes in general economic and
business conditions, inability to maintain market acceptance to the Company's
products, inability to timely develop and introduce new technologies,
products and applications, rapid changes in the market for the Company's
products, loss of market share and pressure on prices resulting from
competition, introduction of competing products by other companies, inability
to manage growth and expansion, loss of key OEM partners, inability to
attract and retain qualified personnel, inability to protect the Company's
proprietary technology.

Furthermore, this press release does not constitute an offer to
sell or a solicitation of an offer to buy any securities. The Company's
shares issued have not been, and will not be, registered under the US
Securities Act of 1933, as amended (the "Securities Act"), or under any of
the relevant Securities Laws of any state of the United States. The Company's
shares may not be offered, sold or delivered, directly or indirectly, to, or
for, the account of any US person (as defined in regulation S under the
Securities Act) in or into the United States, or by use of the US mail, or by
any means or instrumentality of United States interstate commerce, absent
registration, or an exemption from registration under the Securities Act.

For further information please contact:
    Gerry Feldman, President
    Walter Tabachnik, Chief Financial Officer
    Elena Gerberg, Investor Relations (Israel) phone +972-2-589-9159
    Frank Justin, Director of Marketing (US) +1-781-354-8073
    e-mail investor@oridion.com
    website http://www.oridion.com
    
    address Oridion Systems Ltd.
    P.O. Box 45025
    91450 Jerusalem
    Israel